Zhichao He

490 total citations
33 papers, 319 citations indexed

About

Zhichao He is a scholar working on Oncology, Pharmacology and Epidemiology. According to data from OpenAlex, Zhichao He has authored 33 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Pharmacology and 5 papers in Epidemiology. Recurrent topics in Zhichao He's work include Cancer Immunotherapy and Biomarkers (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Drug-Induced Adverse Reactions (4 papers). Zhichao He is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Drug-Induced Adverse Reactions (4 papers). Zhichao He collaborates with scholars based in China, United States and Belgium. Zhichao He's co-authors include Kaifeng Qiu, Junyan Wu, Jianhong Zhu, Yayuan Zheng, Wenxia Zhao, Chuxiong Chen, Lin Yin, Yong Wang, Jianfang Li and Zixian Huang and has published in prestigious journals such as ACS Nano, Analytical Biochemistry and Scientific Reports.

In The Last Decade

Zhichao He

29 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhichao He China 8 92 70 62 52 51 33 319
Yuan Kao United States 12 43 0.5× 49 0.7× 44 0.7× 59 1.1× 10 0.2× 32 377
Yuki Izumi Japan 6 178 1.9× 110 1.6× 51 0.8× 32 0.6× 10 0.2× 17 455
Jingyi Tan China 11 49 0.5× 139 2.0× 27 0.4× 73 1.4× 11 0.2× 24 492
Guming Zou China 10 81 0.9× 60 0.9× 22 0.4× 24 0.5× 10 0.2× 34 420
Shuai Fu China 14 45 0.5× 104 1.5× 131 2.1× 47 0.9× 16 0.3× 52 476
Fenghua Li China 11 52 0.6× 53 0.8× 21 0.3× 16 0.3× 26 0.5× 22 549
Cyrus C. Hsia Canada 11 17 0.2× 69 1.0× 54 0.9× 25 0.5× 9 0.2× 83 541
Zhe Dong China 10 24 0.3× 155 2.2× 31 0.5× 52 1.0× 12 0.2× 31 372
Carmela Morace Italy 13 49 0.5× 57 0.8× 80 1.3× 102 2.0× 8 0.2× 39 417

Countries citing papers authored by Zhichao He

Since Specialization
Citations

This map shows the geographic impact of Zhichao He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhichao He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhichao He more than expected).

Fields of papers citing papers by Zhichao He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhichao He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhichao He. The network helps show where Zhichao He may publish in the future.

Co-authorship network of co-authors of Zhichao He

This figure shows the co-authorship network connecting the top 25 collaborators of Zhichao He. A scholar is included among the top collaborators of Zhichao He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhichao He. Zhichao He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dong, Xianzhen, Zixuan Pang, Jingyuan Shao, et al.. (2025). A Zinc-Citrate Metal–Organic Framework-Based Adaptable Hydrogen Sulfide Delivery System for Regulating Neuroregeneration Microenvironment in Spinal Cord Injury. ACS Nano. 19(25). 22798–22819. 2 indexed citations
2.
Zhang, Wenxuan, Wensheng Wang, Zhichao He, et al.. (2025). Synthesis and characterization of bio-based maltitol modified polybutylene terephthalate. Materials Today Communications. 47. 113212–113212.
3.
4.
Feng, Xin, et al.. (2025). Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis. Clinical Drug Investigation. 45(6). 295–308.
5.
Yang, Zhe, Jiawen Cui, Zhichao He, et al.. (2025). Simplified Mechanistic Aging Model for Lithium Ion Batteries in Large-Scale Applications. Materials. 18(6). 1342–1342. 1 indexed citations
6.
Chen, Mengting, Zhichao He, Jianhong Zhu, et al.. (2024). Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database. Expert Opinion on Drug Safety. 23(4). 497–511. 3 indexed citations
7.
8.
Yang, Yexin, Yi Liu, Yuanyuan Wang, et al.. (2024). Gap-free chromosome-level genomes of male and female spotted longbarbel catfish Hemibagrus guttatus. Scientific Data. 11(1). 572–572. 4 indexed citations
9.
Song, Shuang, Xisheng Tang, Fu Li, et al.. (2024). Fault evolution mechanism for lithium-ion battery energy storage system under multi-levels and multi-factors. Journal of Energy Storage. 80. 110226–110226. 18 indexed citations
10.
Zhu, Jianhong, Jianfang Li, Yayuan Zheng, et al.. (2023). Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology. 125(Pt B). 111184–111184. 2 indexed citations
11.
He, Zhichao, Wei Jiang, Jianhong Zhu, et al.. (2023). Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database. International Journal of Gynecological Cancer. 33(8). 1237–1246. 1 indexed citations
12.
He, Zhichao, Jianhong Zhu, Dan Liang, et al.. (2023). Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opinion on Drug Safety. 22(7). 599–609. 6 indexed citations
13.
Liu, Jiaojiao, Yan Sun, Lin Zhang, et al.. (2023). Screening of antibiotics to obtain axenic cell cultures of a marine microalga Chrysotila roscoffensis. Frontiers in Bioengineering and Biotechnology. 11. 1218031–1218031. 7 indexed citations
14.
He, Zhichao, et al.. (2023). A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma. Analytical Biochemistry. 676. 115230–115230. 5 indexed citations
15.
Zhu, Jianhong, Dan Liang, Yayuan Zheng, et al.. (2022). Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology. 110. 109053–109053. 5 indexed citations
16.
Wu, Junyan, Jianxiang Huang, Jianhong Zhu, et al.. (2022). Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. Expert Opinion on Drug Safety. 22(3). 231–235. 4 indexed citations
17.
He, Zhichao, Wenxia Zhao, Shan Yang, et al.. (2022). SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetologica. 60(3). 401–411. 18 indexed citations
18.
Jiang, Wei, Zhichao He, Tiantian Zhang, et al.. (2021). Cost–Effectiveness Analysis of Ribociclib Plus Fulvestrant for Hormone Receptor-Positive/Human EGF Receptor 2-Negative Breast Cancer. Immunotherapy. 13(8). 661–668. 4 indexed citations
19.
Zhang, Mei, Jianhong Zhu, Zhichao He, et al.. (2020). Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 19(5). 617–623. 7 indexed citations
20.
Qiu, Kaifeng, et al.. (2016). miR-22 regulates cell invasion, migration and proliferation in vitro through inhibiting CD147 expression in tongue squamous cell carcinoma. Archives of Oral Biology. 66. 92–97. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuan Kao Breakdown of academic impact, for papers by Yuki Izumi Breakdown of academic impact, for papers by Jingyi Tan Breakdown of academic impact, for papers by Guming Zou Breakdown of academic impact, for papers by Shuai Fu Breakdown of academic impact, for papers by Fenghua Li Breakdown of academic impact, for papers by Cyrus C. Hsia Breakdown of academic impact, for papers by Zhe Dong Breakdown of academic impact, for papers by Carmela Morace
Rankless by CCL
2026